Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06990087 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

T-cell Therapy in Patients With PML

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 6 to 7
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 8 of 21 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2025 to Feb 6, 2026
    v4
  3. Start date: Sep 2025 to Nov 2025v3
  4. Start date: May 2025 to Sep 2025v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.
Trial Details
NCT Number NCT06990087
Lead Sponsor Hannover Medical School
Conditions
(from sponsor)		 Progressive Multifocal Leucoencephalopathy (PML)
Related terms Leukoencephalopathy, Progressive Multifocal
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov